Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key ...

Studies reveal that the air inside our homes is more polluted than the air outdoors, and a portion of these toxins come from ...

Reports Q4 revenue $118.8M, consensus $117.84M. “2024 was another defining year for Axsome, driven by strong commercial growth and a rapidly ...

Gemma Jolly of medical charity the Migraine Trust said NICE’s recommendation ... have performed well in clinical trials, but so far commercial success has been limited, despite blockbuster ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Axsome Therapeutics Inc (AXSM) reports significant revenue growth driven by Auvelity and Sunosi, while navigating increased R&D expenses and strategic market challenges.

Anniversary Special, and there is a “longstanding” reason.The actor and comedian may have been missing from SNL 50 Live from ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by equities research analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued ...

This week in design, Valentine’s Day might be over, but for some design enthusiasts, heart-shaped bathtubs are forever. Stay ...